Development Plan for Evorpacept
A Synergistic Approach to Cancer Treatment
We are pursuing a robust development plan for evorpacept across a breadth of indications in solid and hematologic cancers with multiple combination partners.
|
Modality/ Target |
Program | Indication |
Phase
IND Enabling
Phase 1
Phase 2
Phase 3
|
Status |
|---|---|---|---|---|
| Evorpacept Programs | ||||
|
Anti-cancer Antibodies
|
ASPEN-Breast
Evorpacept, HERCEPTIN® + chemotherapy
|
Enhertu®-Experienced HER2-Positive Breast Cancer
|
mid phase 2
|
FPI mid-year ’25
|
|
ASPEN-CRC
Evorpacept, ERBITUX®+ chemotherapy
|
2L, EGFR-Naïve Metastatic Colorectal Cancer (CRC)
|
mid phase 1
|
FPI mid-year ’25
|
|
|
SARCLISA® + Dexamethasone¹ + Evorpacept
|
RRMM (Relapsed or Refractory Multiple Myeloma)
|
mid phase 1
|
FPI Q3 ‘24, Currently Enrolling
|
|
|
ASPEN-06
Evorpacept, HERCEPTIN®, CYRAMZA® + Paclitaxel²
|
2L or 3L Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction (GEJ)
|
mid phase 2
|
Completed, established POC, seeking partner ex-US
|
|
|
Zanidatamab³ + Evorpacept
|
HER2-Expressing Breast Cancer and Other Cancers
|
mid phase 2
|
Completed, data presented at SABCS ‘24
|
|
|
ADC
|
Enhertu® (I-SPY)⁴ + Evorpacept
|
HER2-Positive HER2-Low Metastatic Breast Cancer
|
mid/end of phase 1
|
Ongoing
|
| ALX2004 Program | ||||
|
EGFR ADC
|
ALX2004
Dose-escalation and expansion
|
EGFR-Expressing Solid Tumors
|
mid phase 1
|
FPI mid-year ’25
|
Evorpacept Programs
ASPEN-Breast
Evorpacept, HERCEPTIN® + chemotherapy
Modality/Target
Anti-cancer Antibodies
Indication
Enhertu®-Experienced HER2-Positive Breast Cancer
Status
FPI mid-year ’25
Ind
P1
P2
P3
mid phase 2
ASPEN-CRC
Evorpacept, ERBITUX®+ chemotherapy
Modality/Target
Anti-cancer Antibodies
Indication
2L, EGFR-Naïve Metastatic Colorectal Cancer (CRC)
Status
FPI mid-year ’25
Ind
P1
P2
P3
mid phase 1
SARCLISA® + Dexamethasone¹ + Evorpacept
Modality/Target
Anti-cancer Antibodies
Indication
RRMM (Relapsed or Refractory Multiple Myeloma)
Status
FPI Q3 ‘24, Currently Enrolling
Ind
P1
P2
P3
mid phase 1
ASPEN-06
Evorpacept, HERCEPTIN®, CYRAMZA® + Paclitaxel²
Modality/Target
Anti-cancer Antibodies
Indication
2L or 3L Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction (GEJ)
Status
Completed, established POC, seeking partner ex-US
Ind
P1
P2
P3
mid phase 2
Zanidatamab³ + Evorpacept
Modality/Target
Anti-cancer Antibodies
Indication
HER2-Expressing Breast Cancer and Other Cancers
Status
Completed, data presented at SABCS ‘24
Ind
P1
P2
P3
mid phase 2
Enhertu® (I-SPY)⁴ + Evorpacept
Modality/Target
ADC
Indication
HER2-Positive HER2-Low Metastatic Breast Cancer
Status
Ongoing
Ind
P1
P2
P3
mid/end of phase 1
ALX2004 Program
ALX2004
Dose-escalation and expansion
Modality/Target
EGFR ADC
Indication
EGFR-Expressing Solid Tumors
Status
FPI mid-year ’25
Ind
P1
P2
P3
mid phase 1
ALX-Sponsored ongoing Trial
Completed Trial
ALX Oncology retains worldwide rights to evorpacept.
- Sanofi sponsors SARCLISA® clinical trial.
- Lilly supplies CYRAMZA® for ALX Oncology’s ASPEN-06 program
- Jazz Pharmaceuticals sponsors zanidatamab clinical trial.
- Quantum Leap Healthcare Collaborative sponsors I-SPY clinical trial.